This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-20 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
=== Binding site === Agonists and antagonists form certain chemical bonds with amino acids that construct the MOR. The majority of antagonists, as well as agonists, are predicted to form charged interaction with Asp147 and a hydrogen bond with Tyr148. However, majority of antagonists also form additional polar interactions with other amino acid residues such as Lys233, Gln124, Gln229, Asn150, Trp318 and Tyr128. Only a small minority of agonists form the same additional polar interactions. Both agonists and antagonists are known to form hydrogen bonds with His297. It can be concluded that interactions with the amino acid residues, Asp147 and Tyr148 are essential for the ligand to bind to the receptor and the molecules that form additional polar interactions with other residues are more often antagonists than agonists. The N-substituent group can form hydrophobic bonds with Tyr326 and Trp293 and the aromatic and cyclohexane rings can form similar bonds to Met151. The backside of the ligand can also form a hydrophobic bond, but with Val300 and Ile296.
=== Biophysical limitations === The tree of the African locust bean requires "between 0-300 metres of altitude, a mean annual rainfall of between 400-700 millimetres and a mean annual temperature of about 24-28°C." It prefers well-drained, thick clay soils but can also be found on shallow, thin sandy soils.
Taco Bell began experimenting with fast-casual and urban concepts when it created U.S. Taco Co. and Urban Taproom in 2014 reflecting a market shift due to the popularity of Chipotle Mexican Grill. The menu consisted of tacos with American fillings, and did not sell the food sold in Taco Bell restaurants, such as burritos. It was launched in Huntington Beach, California, in August 2014. U.S. Taco Co. closed on September 15, 2015, so the company could focus on its new similar Taco Bell Cantina concept, which featured special menu items and served alcohol. It opened its first location a few days later in Chicago's Wicker Park neighborhood, followed by a location in San Francisco about a month later, located less than a block away from AT&T Park. In 2016, Taco Bell launched the Taco Bell Cantina flagship store located on the Las Vegas Strip. The 24-hour restaurant serves alcohol, unique menu items, and features a DJ. It was announced in August 2017 that the store would begin hosting weddings. Taco Bell Cantina currently has locations in San Francisco, Berkeley, Chicago (2 locations), Las Vegas, Austin, Fayetteville, Cincinnati, Cleveland, Atlanta, Newport Beach, San Diego, San Jose, Sacramento, Nashville, with them once having plans to open soon in Somerville, Massachusetts, but as of 2025, there are instead Taco Bell Cantinas in Brookline and Allston, Massachusetts. In March 2020, Taco Bell announced that it would be converting 3 of its suburban stores into Cantinas that year as part of a test run.
Sources: en.wikipedia.org
TBR1 was identified in 1995 by the Nina Ireland Laboratory of Developmental Neurobiology Center at the University of California, San Francisco. The gene, initially named TES-56, was found to be largely expressed in the telencephalic vesicles of the developing forebrain of mice. The protein product of TES-56 was discovered to be homologous to the Brachyury protein, a T-box transcription factor, which plays a role in establishing symmetry during embryonic development. Thus, due to its relation to T-box genes (such as Tbx-1, Tbx-2, Tbx-3), TES-56 was renamed TBR1. The human TBR1 gene is located on the q arm of the positive strand of chromosome 2. It is 8,954 base pairs in length. TBR1 is one of the three genes that make up the TBR1 subfamily of T-box genes. The two other genes that form the TBR1 subfamily are EOMES (also known as TBR2) and TBX21 (also known as T-BET). TBR1 is also known as T-box Brain Protein, T-Brain 1, and TES-56. The encoded protein consists of 682 amino acid residues and has a predicted molecular weight of 74,053 Da. It is composed of 6 exons.
Stomach upset Intestinal gas Nausea Liver damage (similar to other niacin products) It is marketed as "no-flush" niacin, but research suggests that the lack of flushing may be due to its limited conversion to active niacin. Inositol nicotinate should be used with caution in individuals with certain conditions: Diabetes: May raise blood sugar levels. Diabetic patients should monitor their blood sugar levels closely. Liver disease or kidney disease: Niacin can accumulate in people with liver or kidney problems, potentially worsening their condition. Bleeding disorders: Inositol nicotinate may slow blood clotting, increasing the risk of bleeding for individuals with clotting disorders or those undergoing surgery. Gout: Large amounts of niacin may trigger gout attacks.
=== Introduction of consumer-ready hardware (2010s–present) === The popularity of digital gaming across multiple forms like mobile, console, or PC gaming, led technology giants to further invest in the development of VR technology. In a thriving gaming market, the advancement in VR technology has been a point of great interest in the age of modern gaming. One catalyst to this modern VR boom was the obsession and great success of Pokémon Go in 2016, which incorporated basic VR concepts, stirring the world with technological breakthroughs in gaming such as VR effects, combining real life scenes with the virtual world, as well as the concept of enjoying gaming alongside interaction in the real world. After decades of attempts from its introduction, low-cost, consumer-grade VR hardware began to appear in the 2010s. The Oculus Rift is considered the first consumer-ready VR headset and was first released in 2016. The unit was developed by Palmer Luckey, and first announced in 2013 as an inexpensive VR option for video games. During testing, Luckey had gained the help of id Software's John Carmack to develop a VR version of Doom 3 for Oculus. While this helped to successfully demonstrate the Oculus, which led to Facebook acquiring Oculus in 2014 for $2 billion, it also led to a lawsuit between ZeniMax Media, id's parent company, against Oculus over intellectual property theft over Carmack's participation. The case was settled out of court. Nine games were available at launch and Oculus had established a number of partnerships to provide more games following its release.
Methamphetamine and Native Americans Race and crime Race and crime in the United States Race in the United States criminal justice system Racial profiling in the United States United States incarceration rate
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.